Uncategorized

March 29, 2026

ctDNA Blood Test May Help Predict Anal Cancer Recurrence After Chemoradiation

Charles H. Weaver, MD
January 28, 2026

New Latitude Blood Test Expands MRD Access Beyond Tumor Tissue–Dependent Options in Colorectal Cancer

Charles H. Weaver, MD
December 19, 2025

The Big Picture: Medical Breakthroughs in 2025

Charles H. Weaver, MD
December 15, 2025

New Research at ASH 2025 Points to More Targeted and Personalized Care for People with MPNs

Charles H. Weaver, MD
December 8, 2025

FDA Approves New Blood Test to Help Diagnose High-Grade Prostate Cancer

Meg Monday
November 21, 2025

GLP‑1 Drugs Linked to Better 5‑Year Survival in Colon Cancer Patients With Severe Obesity

Charles H. Weaver, MD
July 7, 2025

Breastfeeding for At Least Six Months May Help Lower Risk of Aggressive Breast Cancer

Charles H. Weaver, MD
$FDA Expands Monjuvi Approval to Include Relapsed or Refractory Follicular Lymphoma$

June 24, 2025

FDA Expands Monjuvi Approval to Include Relapsed or Refractory Follicular Lymphoma

Charles H. Weaver, MD
June 23, 2025

FDA Grants Accelerated Approval for Datroway in EGFR-Mutated Non-Small Cell Lung Cancer

Charles H. Weaver, MD
June 18, 2025

Promising Results for Bexmarilimab Plus Azacitidine in High-Risk MDS

Charles H. Weaver, MD
June 17, 2025

FDA Approves First Nonsurgical Treatment for Recurrent, Low-Grade, Intermediate-Risk NMIBC

Charles H. Weaver, MD
June 16, 2025

FDA Approves Talectrectinib (Ibtrozi) for ROS1-Positive Lung Cancer

Charles H. Weaver, MD